bs_bs_banner
10
ANZUP Annual Scientific Meeting
International Speakers Theodore DeWeese MD Dr. DeWeese is the Sidney Kimmel Professor and Director of the Department of Radiation Oncology and Molecular Radiation Sciences at Johns Hopkins University. He is also Professor of Urology and Oncology at Johns Hopkins. His research has been funded by the NIH, DOD, and foundations for over 15 years and has focused on the identification of genetic mechanisms of radiation response as well as the development of novel cancer therapeutics that also serve as radiation sensitizers. This has included a P01 grant on which he served as PI. He sees and treats men with prostate cancer and actively conducts therapeutic and non-therapeutic clinical trials for these patients. Dr. DeWeese is a senior member of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and sits on its advisory board. He has mentored more than 20 predoctoral students and more than 15 post-doctoral trainees, many of whom have gone on to productive academic careers in the United States and England and has served on 6 thesis committees. He also has served on the cancer center advisory boards of several prominent cancer centers and as ad hoc advisor for scientific research programs and clinical radiation oncology departments at several large academic medical centers. With his scientific, clinical, educational, and managerial background as well as his service as advisor to large, multidisciplinary cancer centers in the United States, Dr. DeWeese has a broad experience on which to draw regarding basic and translational cancer research and has demonstrated his ability to critically evaluate and effectively advise research programs. Sponsored by ANZUP
Brian Rini MD, FACO Brian I. Rini, MD, FACP is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, Ohio. A Staff member of the Department of Solid Tumor Oncology and Co-Leader of the Genitourinary Program of the
CASE Comprehensive Cancer Center, Dr. Rini’s work focuses on genitourinary malignancies. Dr. Rini earned his medical degree at the Ohio State University College of Medicine. After completing a residency program in internal medicine at University of Chicago Hospitals, Dr. Rini was awarded a fellowship in hematology and oncology at the University of Chicago. Dr. Rini was an Assistant Professor at the University of California San Francisco before moving to Cleveland Clinic. At Cleveland Clinic, Dr. Rini’s primary research has been in renal cell carcinoma (RCC), with special focus on antiangiogenic therapy and immunotherapy. Dr. Rini has been involved in the initial and ongoing development of targeted agents for metastatic RCC, and was an integral investigator in the clinical development of these agents which are now FDA approved. Dr. Rini was the Principal Investigator of an international phase III cooperative group trial of bevacizumab plus interferon in metastatic RCC that lead to FDA approval, the registration phase III AXIS trial of axitinib and is currently the PI of another ongoing global phase III trial in RCC. In addition, he is PI of several investigator-initiated phase II trials of targeted therapy in metastatic RCC. Dr. Rini’s research has been published in peer-reviewed journals that include Journal of the National Cancer Institute, Journal of Clinical Oncology, Cancer, Lancet and JAMA. Significantly, he has published major review articles in the Journal of Clinical Oncology, Cancer, Lancet, and Lancet Oncology. He is a member of the editorial boards of Journal of Clinical Oncology, Lancet Oncology, Cancer Research and British Journal of Urology. Certified in Medical Oncology by the American Board of Internal Medicine, Dr. Rini is active in numerous professional organizations, including the American Society of Clinical Oncology (ASCO), American Association for Cancer Research and the Kidney Cancer Association National Medical Advisory Board. He serves as the co-chair of the NCI RCC Task Force, on the ASCO Board of Experts and on the External Review Board for the ASCO Cancer Therapy Evaluation Program. Sponsored by Pfizer
11
International Speakers
Chris Sweeney MBBS Christopher J. Sweeney, received his medical degree from the University of Adelaide, South Australia in 1992, and completed an internship at the Royal Adelaide Hospital. From 1994 to 1997, Dr. Sweeney was an Internal Medicine resident at Gundersen Lutheran Medical Center, La Crosse, Wisconsin, and from 1997 to 2000, he was a Fellow in Hematology/Oncology at Indiana University Medical Center. Dr. Sweeney is certified by the American Board of Internal Medicine in Medical Oncology. He has held faculty appointments at Indiana University and Royal Adelaide Hospital. In 2009 he joined the Lank Center for Genitourinary Oncology at the Dana Farber Cancer Institute and in 2012 became Clinical Director. He is an Associate Professor at Harvard Medical School. He is a member of the American Society of Clinical Oncology, Eastern Cooperative Oncology Group, Alliance and American Association for Cancer Research. Dr. Sweeney has served as the Associate Director for Clinical Research for the NCI-designated, Indiana University Simon Cancer Center and Co-Leader of the Experimental Developmental Therapeutics Program, and Chairman of the Hoosier Oncology Group from 2005 to 2007. Dr. Sweeney has served on the Program Committee and the Cancer Education Committee of the American Society of Clinical Oncology and has been on the Editorial Board for ASCOs “Journal of Clinical Oncology”. He has received peer reviewed funding from the National Institutes of Health and the Department of Defense, Lance Armstrong Foundation, and PhRMA. He has also served on the Scientific Advisory Board of biotech companies both in Australia and USA. His research has focused on drug development and identify markers of response to therapy with a focus on prostate cancer. Sponsored by Astellas
Bertrand Tombal MD, PhD Professor Bertrand Tombal is Chairman of the Division of Urology and Professor of Urology at the Université catholique de Louvain (UCL), Cliniques universitaires Saint-Luc, Brussels, Belgium. He is member of the Belgian Royal Academy of Medicine. He is the current chairman of the Genitourinary group of European Organization for Research and Treatment in Cancer, the leading European academic research organization in the field of cancer. He has both a basic science and a clinical interest in urological oncology, particularly in the field of prostate and bladder cancer. Professor Tombal obtained his MD in 1990 and his PhD in 2003, both from the Université catholique de Louvain. During his PhD, he studied the mechanisms involved in apoptosis of prostate cancer cells and the modulation of apoptosis by growth factors. He completed part of his basic sciences training at Johns Hopkins University, Baltimore, MD, USA. Professor Tombal’s primary clinical interest is the treatment of advanced stages of prostate cancer, and particularly hormonal treatment and development of new biological agents. He is heading the uro-oncology division at the Université catholique de Louvain where he is coordinating several trials in this research area. In addition, Professor Tombal has authored many published papers, books, and bookchapters. He has presented at numerous national and international conferences and has been the recipient of various awards for his research in the field of urology, including the European Association of Urology thesis award, which he received in 2003. Professor Tombal is also member of Belgium College of Urology, the Skeletal Care Academy, and member of the Scientific Office of European Association of Urology. Sponsored by Ipsen
10
ANZUP Annual Scientific Meeting
International Speakers Theodore DeWeese MD Dr. DeWeese is the Sidney Kimmel Professor and Director of the Department of Radiation Oncology and Molecular Radiation Sciences at Johns Hopkins University. He is also Professor of Urology and Oncology at Johns Hopkins. His research has been funded by the NIH, DOD, and foundations for over 15 years and has focused on the identification of genetic mechanisms of radiation response as well as the development of novel cancer therapeutics that also serve as radiation sensitizers. This has included a P01 grant on which he served as PI. He sees and treats men with prostate cancer and actively conducts therapeutic and non-therapeutic clinical trials for these patients. Dr. DeWeese is a senior member of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and sits on its advisory board. He has mentored more than 20 predoctoral students and more than 15 post-doctoral trainees, many of whom have gone on to productive academic careers in the United States and England and has served on 6 thesis committees. He also has served on the cancer center advisory boards of several prominent cancer centers and as ad hoc advisor for scientific research programs and clinical radiation oncology departments at several large academic medical centers. With his scientific, clinical, educational, and managerial background as well as his service as advisor to large, multidisciplinary cancer centers in the United States, Dr. DeWeese has a broad experience on which to draw regarding basic and translational cancer research and has demonstrated his ability to critically evaluate and effectively advise research programs. Sponsored by ANZUP
Brian Rini MD, FACO Brian I. Rini, MD, FACP is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, Ohio. A Staff member of the Department of Solid Tumor Oncology and Co-Leader of the Genitourinary Program of the
CASE Comprehensive Cancer Center, Dr. Rini’s work focuses on genitourinary malignancies. Dr. Rini earned his medical degree at the Ohio State University College of Medicine. After completing a residency program in internal medicine at University of Chicago Hospitals, Dr. Rini was awarded a fellowship in hematology and oncology at the University of Chicago. Dr. Rini was an Assistant Professor at the University of California San Francisco before moving to Cleveland Clinic. At Cleveland Clinic, Dr. Rini’s primary research has been in renal cell carcinoma (RCC), with special focus on antiangiogenic therapy and immunotherapy. Dr. Rini has been involved in the initial and ongoing development of targeted agents for metastatic RCC, and was an integral investigator in the clinical development of these agents which are now FDA approved. Dr. Rini was the Principal Investigator of an international phase III cooperative group trial of bevacizumab plus interferon in metastatic RCC that lead to FDA approval, the registration phase III AXIS trial of axitinib and is currently the PI of another ongoing global phase III trial in RCC. In addition, he is PI of several investigator-initiated phase II trials of targeted therapy in metastatic RCC. Dr. Rini’s research has been published in peer-reviewed journals that include Journal of the National Cancer Institute, Journal of Clinical Oncology, Cancer, Lancet and JAMA. Significantly, he has published major review articles in the Journal of Clinical Oncology, Cancer, Lancet, and Lancet Oncology. He is a member of the editorial boards of Journal of Clinical Oncology, Lancet Oncology, Cancer Research and British Journal of Urology. Certified in Medical Oncology by the American Board of Internal Medicine, Dr. Rini is active in numerous professional organizations, including the American Society of Clinical Oncology (ASCO), American Association for Cancer Research and the Kidney Cancer Association National Medical Advisory Board. He serves as the co-chair of the NCI RCC Task Force, on the ASCO Board of Experts and on the External Review Board for the ASCO Cancer Therapy Evaluation Program. Sponsored by Pfizer
11
International Speakers
Chris Sweeney MBBS Christopher J. Sweeney, received his medical degree from the University of Adelaide, South Australia in 1992, and completed an internship at the Royal Adelaide Hospital. From 1994 to 1997, Dr. Sweeney was an Internal Medicine resident at Gundersen Lutheran Medical Center, La Crosse, Wisconsin, and from 1997 to 2000, he was a Fellow in Hematology/Oncology at Indiana University Medical Center. Dr. Sweeney is certified by the American Board of Internal Medicine in Medical Oncology. He has held faculty appointments at Indiana University and Royal Adelaide Hospital. In 2009 he joined the Lank Center for Genitourinary Oncology at the Dana Farber Cancer Institute and in 2012 became Clinical Director. He is an Associate Professor at Harvard Medical School. He is a member of the American Society of Clinical Oncology, Eastern Cooperative Oncology Group, Alliance and American Association for Cancer Research. Dr. Sweeney has served as the Associate Director for Clinical Research for the NCI-designated, Indiana University Simon Cancer Center and Co-Leader of the Experimental Developmental Therapeutics Program, and Chairman of the Hoosier Oncology Group from 2005 to 2007. Dr. Sweeney has served on the Program Committee and the Cancer Education Committee of the American Society of Clinical Oncology and has been on the Editorial Board for ASCOs “Journal of Clinical Oncology”. He has received peer reviewed funding from the National Institutes of Health and the Department of Defense, Lance Armstrong Foundation, and PhRMA. He has also served on the Scientific Advisory Board of biotech companies both in Australia and USA. His research has focused on drug development and identify markers of response to therapy with a focus on prostate cancer. Sponsored by Astellas
Bertrand Tombal MD, PhD Professor Bertrand Tombal is Chairman of the Division of Urology and Professor of Urology at the Université catholique de Louvain (UCL), Cliniques universitaires Saint-Luc, Brussels, Belgium. He is member of the Belgian Royal Academy of Medicine. He is the current chairman of the Genitourinary group of European Organization for Research and Treatment in Cancer, the leading European academic research organization in the field of cancer. He has both a basic science and a clinical interest in urological oncology, particularly in the field of prostate and bladder cancer. Professor Tombal obtained his MD in 1990 and his PhD in 2003, both from the Université catholique de Louvain. During his PhD, he studied the mechanisms involved in apoptosis of prostate cancer cells and the modulation of apoptosis by growth factors. He completed part of his basic sciences training at Johns Hopkins University, Baltimore, MD, USA. Professor Tombal’s primary clinical interest is the treatment of advanced stages of prostate cancer, and particularly hormonal treatment and development of new biological agents. He is heading the uro-oncology division at the Université catholique de Louvain where he is coordinating several trials in this research area. In addition, Professor Tombal has authored many published papers, books, and bookchapters. He has presented at numerous national and international conferences and has been the recipient of various awards for his research in the field of urology, including the European Association of Urology thesis award, which he received in 2003. Professor Tombal is also member of Belgium College of Urology, the Skeletal Care Academy, and member of the Scientific Office of European Association of Urology. Sponsored by Ipsen
